anti-LILRB4 monoclonal antibody BND-35

{
  "id": "MLC-T-ONC-010867",
  "term": "anti-LILRB4 monoclonal antibody BND-35",
  "field": "Oncology and biomedicine",
  "definition": "A humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the myeloid-enriched immune inhibitory receptor leukocyte immunoglobulin-like receptor B member 4 (LILRB4; ILT3; ILT-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody BND-35 targets, binds to and blocks LILRB4, thereby preventing the interaction with its ligands, such as fibronectin, in the tumor microenvironment (TME). This prevents the activation of LILRB4-mediated downstream signaling pathways. This may abrogate LILRB4-mediated promotion of myeloid cell immunosuppression and inhibition of antitumor immunity. This may restore immune function by activating dendritic cells (DCs) and T cells, and may promote T-cell-mediated immune responses against tumor cells. LILRB4, an inhibitory immune receptor highly expressed on tumor-associated myeloid cells, primarily tolerogenic DCs, myeloid-derived suppressor cells (MDSCs) and M2 macrophages, functions as an immune checkpoint that negatively regulates DC- and T-cell activation. It is upregulated in several tumor types and plays an important role in tumor infiltration, immunosuppression and immune tolerance.",
  "synonyms": [
    "anti-ILT3 monoclonal antibody BND-35",
    "ILT3 antagonist antibody BND-35"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-lilrb4-monoclonal-antibody-bnd-35/"
}